SUBSCRIBE: Print / eNewsletter
Blase Polite on How Disparities Research Must Move Into an Era of Action
In this interview we discuss health disparities in cancer care, how redesigning cancer clinical trials can address some of these disparities, and goals for the “next generation” of cancer health disparities research.
Preserving Fertility in BRCA-Positive Breast Cancer
In this interview we discuss a recent study presented at ESMO on fertility-preserving procedures for women with BRCA-positive breast cancers
David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer
In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.
Breast Implants Linked to Anaplastic Large-Cell Lymphoma
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.
Fay Hlubocky on Recognizing and Addressing Clinician Burnout
In this interview we discuss the issue of burnout in oncology, including signs and risk factors, how it might affect patient care, and strategies for prevention.
New ASCO Guideline on Second-Line Hormone Therapy in Prostate Cancer
In this interview we discuss the ASCO provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer.
Jeffrey Vacirca on How the COA Advocates for Community Oncology Practices and Patients
In this interview we discuss the goals of the Community Oncology Alliance, highlights from their annual meeting, and the challenge of transitioning cancer care to the hospital setting.
Does WBRT Still Have a Role for Cancer Patients With Brain Metastases?
In this interview we discuss new data on the use of radiotherapy in cancer patients with brain metastases.
Role of Gut Microbiome in Metastatic Melanoma Patients on Immunotherapy
In this interview we discuss the effect of the gut microbiome on responses and survival outcomes in metastatic melanoma patients treated with anti–PD-1 immunotherapies.
Novel Therapies in Development for HER2-Amplified Breast Cancer
In this interview we discuss some of the novel therapeutics in development for HER2-amplified breast cancer.